Tested in animal models, it may extend cognitive function by 10-15 years, offering a potential breakthrough in Alzheimer’s ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling hope it could one day work in humans.

Officials said over 71,000 Oklahomans are currently living with Alzheimer's disease. Nationally, that number is approaching 7 ...

Trajectories of frailty increased more rapidly 4 to 9 years before dementia onset. Even before this acceleration, higher ...

And also we found the significant effects in terms of ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognitive Subscale], ...

Actinogen reports its advanced Alzheimer's disease trial is recruiting strongly, with first results expected by mid next year ...

Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q3 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc.

From advanced imaging to AI-driven analysis, we seek studies that not only push the boundaries of what is possible but also directly address the clinical needs of conditions such as ALS, Autism, ...

There are a series of molecules in clinical trials, 16 in phase III, with different mechanisms of action. Some are small; ...

Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside ...

An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...

Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...